CICC Research Forecasts Strong Price Appreciation for Corteva (NYSE:CTVA) Stock

Corteva (NYSE:CTVA) had its price objective lifted by equities research analysts at CICC Research from $70.00 to $80.00 in a report released on Wednesday,MarketScreener reports. The brokerage currently has an “outperform” rating on the stock. CICC Research’s price target points to a potential upside of 8.12% from the stock’s previous close.

A number of other equities analysts have also commented on the company. Oppenheimer set a $86.00 price target on Corteva in a research note on Thursday, February 5th. UBS Group cut shares of Corteva from a “buy” rating to a “hold” rating in a research report on Monday. BNP Paribas Exane increased their price objective on shares of Corteva from $70.00 to $72.00 and gave the company a “neutral” rating in a research report on Monday, November 17th. The Goldman Sachs Group restated a “buy” rating and issued a $88.00 target price on shares of Corteva in a report on Thursday, February 5th. Finally, Rothschild & Co Redburn lowered their price target on shares of Corteva from $71.00 to $65.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $82.20.

Corteva Trading Down 1.8%

Shares of Corteva stock opened at $73.99 on Wednesday. Corteva has a fifty-two week low of $53.40 and a fifty-two week high of $77.41. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.96 and a current ratio of 1.43. The company has a market capitalization of $50.00 billion, a P/E ratio of 46.83, a P/E/G ratio of 2.57 and a beta of 0.75. The company has a fifty day moving average of $69.49 and a 200 day moving average of $68.45.

Corteva (NYSE:CTVA) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The firm’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.32 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, sell-side analysts anticipate that Corteva will post 2.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Corteva

Institutional investors and hedge funds have recently modified their holdings of the business. Gladwyn Financial Advisors Inc. purchased a new stake in shares of Corteva during the second quarter valued at $25,000. Total Investment Management Inc. purchased a new position in Corteva in the 2nd quarter worth about $27,000. Activest Wealth Management lifted its holdings in Corteva by 118.3% during the 3rd quarter. Activest Wealth Management now owns 369 shares of the company’s stock valued at $25,000 after buying an additional 200 shares in the last quarter. Curat Global LLC boosted its position in Corteva by 93.7% in the 2nd quarter. Curat Global LLC now owns 370 shares of the company’s stock valued at $28,000 after buying an additional 179 shares during the period. Finally, JPL Wealth Management LLC bought a new position in Corteva in the 3rd quarter worth about $25,000. 81.54% of the stock is owned by institutional investors.

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.